Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2025)

Historic Work In Process for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $29.2 million.

  • Ultragenyx Pharmaceutical's Work In Process rose 4391.8% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 4391.8%. This contributed to the annual value of $22.0 million for FY2024, which is 1648.02% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Work In Process of $29.2 million as of Q3 2025, which was up 4391.8% from $19.8 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Work In Process peaked at $29.2 million during Q3 2025, and registered a low of $6.8 million during Q1 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Work In Process value was $18.5 million (recorded in 2023), while the average stood at $17.5 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Work In Process surged by 7675.07% in 2022 and then plummeted by 2176.86% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Work In Process stood at $10.5 million in 2021, then skyrocketed by 66.47% to $17.5 million in 2022, then rose by 7.85% to $18.9 million in 2023, then increased by 16.48% to $22.0 million in 2024, then surged by 32.87% to $29.2 million in 2025.
  • Its last three reported values are $29.2 million in Q3 2025, $19.8 million for Q2 2025, and $22.9 million during Q1 2025.